The Drug Eluting Balloons Catheters Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Drug Eluting Balloons Catheters Market:
https://www.thebusinessresearchcompany.com/report/drug-eluting-balloons-catheters-global-market-report
According to The Business Research Company’s Drug Eluting Balloons Catheters Global Market Report 2024, The drug eluting balloons catheters market size has grown rapidly in recent years. It will grow from $1.23 billion in 2023 to $1.43 billion in 2024 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to increasing respiratory disorders, advantages over traditional inhalers, patient preference for dpis, government initiatives for respiratory health, strategic collaborations and partnerships, advancements in drug formulations, rising geriatric population..
The drug eluting balloons catheters market size is expected to see rapid growth in the next few years. It will grow to $2.35 billion in 2028 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to continued growth in respiratory disorders, expanding geriatric population, increasing awareness and education, market expansion in emerging economies, customized drug formulations, regulatory support and compliance, innovations in packaging and design.. Major trends in the forecast period include smart inhalers and connectivity, shift towards breath-actuated inhalers, focus on pediatric and geriatric patient needs, biologics delivery, environmentally friendly inhaler designs..
The growing prevalence of peripheral and cardiovascular diseases is expected to propel the growth of the drug-eluting balloon catheter market going forward. Cardiovascular diseases (CVDs) refer to a group of conditions that impact the heart and the circulatory system, whereas peripheral artery disease (PAD) specifically refers to a condition where narrowed arteries reduce blood flow primarily to the arms or legs. Drug-eluting balloon catheters are a type of treatment for coronary artery disease (CAD) that uses a semi-compliant angioplasty balloon coated with an anti-proliferative substance that, when it enters the vessel, can have an anti-restenotic effect. For instance, in April 2023, according to the British Heart Foundation, a UK-based cardiovascular research charity, the number of deaths from coronary heart disease in the UK in 2021 was 65,579, up from 64,170 in 2020. Furthermore, in April 2023, according to HMP Global, a US-based multi-accredited patient-centered education company, it is projected that the prevalence of peripheral arterial disease in the US will reach 23.8 million in 2030, up from 21.0 million in 2020. Therefore, the growing prevalence of peripheral and cardiovascular diseases is driving the drug-eluting balloon catheter market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=13429&type=smp
The drug eluting balloons catheters market covered in this report is segmented –
1) By Product: Coronary Artery Disease Drug-Eluting Balloon Catheters, Peripheral Vascular Disease Drug-Eluting Balloon Catheters
2) By Drug: Paclitaxel, Sirolimus, Other Drugs
3) By Raw Material: Nylon, Polyurethane, Other Raw Materials
4) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Catheterization Laboratories
Major companies operating in the drug-eluting balloon catheter market are increasing their focus on developing the newest-generation products with advanced technologies to gain a competitive edge in the market. For instance, in July 2021, Medtronic PLC, an Ireland-based medical technology company, launched Prevail DCB in Europe, its latest-generation drug-coated balloon catheter for the treatment of coronary artery disease. This device is specifically designed for use in PCI (percutaneous coronary intervention) procedures, assisting in the treatment of constricted or obstructed coronary arteries associated with coronary artery disease (CAD). The Prevail DCB employs paclitaxel, a drug that’s quickly absorbed, to effectively treat new lesions, issues in small vessels, and in-stent restenosis (ISR). Furthermore, by integrating PowerTrac, a cutting-edge technology previously found in the delivery system for the Medtronic Resolute Onyx DES, it provides superior deliverability and pushing power.
The drug eluting balloons catheters market report table of contents includes:
- Executive Summary
- Drug Eluting Balloons Catheters Market Characteristics
- Drug Eluting Balloons Catheters Market Trends And Strategies
- Drug Eluting Balloons Catheters Market- Macro Economic Scenario
- Global Drug Eluting Balloons Catheters Market Size and Growth
.
.
.
- Global Drug Eluting Balloons Catheters Market Competitive Benchmarking
- Global Drug Eluting Balloons Catheters Market Competitive Dashboard
- Key Mergers And Acquisitions In Drug Eluting Balloons Catheters Market
- Drug Eluting Balloons Catheters Market Future Outlook and Potential Analysis
- Appendix
Top Major Players :
- Abbott Laboratories
- Medtronic PLC
- Becton Dickinson and Company
- Koninklijke Philips NV
- Boston Scientific Corporation
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
